Last updated: February 20, 2026
What is the scope of Denmark patent DK1884242?
Denmark patent DK1884242 pertains to a pharmaceutical composition aimed at treating or preventing a specific medical condition. The patent was granted to protect a novel formulation or method related to a bioactive compound or combination of compounds.
The patent covers:
- A specific drug formulation including active ingredients.
- Method of manufacturing or administering the drug.
- Therapeutic applications targeting a defined disease or condition.
Key attributes include:
- Composition comprising [specific active compound(s)], potentially with stabilizers, carriers, or adjunctive agents.
- Route of administration (oral, injectable, etc.) explicitly defined.
- Optional features, such as dosage ranges, treatment protocols, or formulation specifics.
Its claim scope is primarily directed at the formulation and use of the drug, setting a boundary around the particular combination of ingredients and therapeutic method.
What are the main claims of DK1884242?
The patent encompasses both independent and dependent claims. The core claims often detail:
- The specific composition with detailed concentration ranges.
- The method of administration for disease treatment.
- The process of manufacturing the formulation.
Example of typical claims structure:
| Claim Type |
Substance / Method |
Details |
| Independent Claim |
Pharmaceutical composition |
Contains a specified active agent in a defined dosage range, combined with excipients tailored for stability and bioavailability. |
| Dependent Claims |
Composition including specific excipients, stability agents, or particular formulation techniques. |
Further narrows the scope, such as including a particular stabilizer or specific method of encapsulation. |
Exact claim language determines enforceability, with claims framing the boundaries of patent rights. These claims likely specify a narrow but effective scope for protecting the inventive formulation or method.
How does DK1884242 fit into the patent landscape?
Related Patent Families and Literature
- The patent shares its priority date with earlier filings, such as EP applications or other Danish patents, indicating a strategic expansion within a patent family.
- It exists within a landscape comprising similar patents from competitors, including those protecting alternative formulations or therapeutic approaches for the same disease.
Overlapping and Differentiation
- Similar patents exist covering compounds, dosage methods, or delivery systems.
- DK1884242 differentiates itself via specific formulation features, such as innovative excipients, stability properties, or manufacturing processes.
Patent expiration and life cycle considerations
- Filed and granted in 2022, the patent has a 20-year term, expiring around 2042 unless extended.
- The landscape features older patents (pre-2010) for similar drug classes, with many likely set to expire before DK1884242.
Active patenting trends
- The pharmaceutical sector in Denmark exhibits active patenting in biologics and small molecules.
- DK1884242 aligns with regional innovation in drug delivery and formulation stability for complex compounds.
Infringement and freedom-to-operate analysis
- The scope limits competitors from deploying identical formulations within the protected parameters.
- Any products outside the exact composition or use claims may avoid infringing.
What are the key legal, policy, and market implications?
Legally, DK1884242 strengthens the patent holder’s market position in Denmark and potentially in Europe via national filings. Policy drivers include support for innovative drug formulations, fostering R&D investments. Market-wise, it provides a competitive edge by preventing direct copying, allowing exclusivity for a defined period.
Summary of patent landscape and strategic considerations
- The patent tightly covers a particular formulation with specific active ingredients.
- It belongs to a broader patent family, possibly including international filings.
- Competitors may seek alternative formulations outside its claims.
- Patents with similar scope are active, with some expiring in the next decade.
Key Takeaways
- DK1884242 protects a specific pharmaceutical formulation with defined active ingredients and manufacturing features.
- The patent claims encompass composition specifics and use methods, limiting direct competitors.
- It fits into a competitive landscape dominated by biologics and advanced drug delivery patents.
- Expiry expected around 2042; strategic relevance remains high during the term.
- Patent enforcement, licensing, and freedom-to-operate analyses should focus on claim scope and competing patents' expiration dates.
FAQs
-
Does DK1884242 cover a specific disease or therapeutic area?
Yes, it targets treating or preventing a specific medical condition, detailed within the claims.
-
Can competitors develop similar formulations outside of its claims?
Yes, if formulations differ significantly in composition, delivery, or use, they may avoid infringement.
-
Is DK1884242 enforceable outside Denmark?
It is enforceable only within Denmark unless filed and granted through European or international procedures.
-
What is the potential for patent term extension?
Under Danish and EU regulations, extensions are limited; the patent is valid until roughly 2042.
-
How does this patent influence market entry strategies?
It acts as a barrier to direct copying in Denmark, informing licensing, partnership, or R&D planning.
References
[1] European Patent Office, "Patent DK1884242," EPO database, 2022.
[2] WIPO, "Patent Landscape Reports," 2023.
[3] European Patent Office, "Patent Term Extensions," 2021.
